Senator for Victoria

Media Releases

Life-Changing Medicines Listings To Save Cystic Fibrosis Patients Up To $250,000 A Year

Tuesday, 22 October 2019

Life-Changing Medicines Listings To Save Cystic Fibrosis Patients Up To $250,000 A Year

Nationals Senator for Victoria Bridget McKenzie says the Liberal-Nationals Government announcement to provide immediate access to life-changing medicines on the Pharmaceutical Benefits Scheme (PBS) will make a real difference for people with cystic fibrosis.

From 1 December 2019, the life-changing cystic fibrosis medicine Symdeko® will be listed on the PBS for patients with cystic fibrosis over the age of 12, who have specific gene mutations, saving families up to $250,000 a year.

The current listing of Orkambi® will also be expanded for children aged 2-5 years of age, allowing earlier access to this life changing medicine.

Senator McKenzie said it was another example of the Nationals in government’s commitment to “saving lives and protecting lives.”

“The average life expectancy for Australians with cystic fibrosis is 38, still less than half that of the average Australian,” Senator McKenzie said.

“This is why it is so important to provide access to new medicines that can extend the lives of people with cystic fibrosis.”

Patients can gain access to Symdeko® and Orkambi® immediately, with the manufacturer agreeing to the government’s request to provide early access, until the medicine is listed on the PBS on 1 December.

Minister for Health, Greg Hunt, said the new and amended listings were “expected to provide new or improved treatment options for over 1400 patients.”

“People might otherwise pay up to $250,000 a year for Symdeko®, or for Orkambi®, but with the government’s investment they will now only pay a maximum of $40.30 per script, with concessional people paying just $6.50,” Minister Hunt said.

In Australia, one in 2,500 babies are born with cystic fibrosis, and there is currently no cure.

Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time. A defective gene causes a thick, sticky build-up of mucus in the lungs, pancreas, and other organs.

The Pharmaceutical Benefits Advisory Committee (PBAC) recommended these medicines be listed on the PBS. PBAC is independent of Government by law and in practice.

By law, the Federal Government cannot list a new medicine without a positive recommendation from PBAC. We are subsidising all drugs recommended by the independent medical experts.

Since 2013, the government has listed more than 2,200 new or amended items on the PBS. This represents an average of about 30 listings a month – or one each day – at an overall cost of around $10.6 billion.

Senator McKenzie said The Nationals’ commitment to ensuring rural and regional Australians can access affordable medicines remains rock solid.

More information these new PBS listings: 

Symdeko® will be made available through the PBS for the treatment of people with cystic fibrosis who have two copies of the f508del mutation in the CFTR gene, and are 12 years or older. 

Symdeko will also be made available for people with cystic fibrosis who have only one copy of the f508del mutation, and have one other residual function mutation, and are 12 years or older.

The current listing of Orkambi®, used to treat people with cystic fibrosis who have two copies of the F508del mutation in the CFTR gene, will be expanded so that children can commence subsidised treatment from two years of age, instead of six years of age.


© Senator Bridget McKenzie 2014 | Authorised by Senator Bridget McKenzie, National Party of Australia, Bendigo Victoria 3550
Datasearch Web Design | Privacy Policy & Disclaimer | Accessibility Policy | Login